DOJ reportedly preparing suits against Aetna-Humana, Anthem-Cigna mergers

Reuters and Bloomberg have reported the U.S. Department of Justice (DOJ) will soon file lawsuits to block two pending mergers between major health insurers: Anthem’s acquisition of Cigna and Aetna’s takeover of Humana.

Both stories cite “sources familiar with the matter,” who said the DOJ is concerned about healthcare costs increasing if four of the five largest insurers in the U.S. consolidate. A July 8 report from Reuters said the DOJ had “significant concerns” about the Aetna-Humana deal, and since then, Aetna has begun looking for buyers for its Medicare Advantage business to ease antitrust concerns. According to Bloomberg, those efforts aren’t likely satisfy federal officials.

The rumored DOJ lawsuits would be exactly what several groups of politicians and state regulators have requested over the past several months:

  • On May 24, Missouri’s insurance department issued an order against the Aetna-Humana merger over its “anticompetitive impact."
  • On June 16, California Insurance Commissioner Dave Jones asked the DOJ to block the Anthem-Cigna deal, saying “More competition in California's consolidated health insurance markets is needed, not less.”
  • On June 22, seven Democratic U.S. Senators wrote a letter to the DOJ asking it to challenge the deals, arguing the result will be higher premiums and reduced access to care.

Not all state agencies have opposed the deal—18 state insurance regulators signed off on the Aetna-Humana deal, and another 10 approved the Anthem-Cigna merger.

“We are steadfast in our belief that this deal is good for consumers and the health-care system as a whole,” T.J. Crawford, an Aetna spokesman, said to Bloomberg.

Bloomberg's and Reuters’ sources indicate the suits could be filed as early as next week. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.